FierceBiotech4h
Sling's oral Tepezza rival hits goal in thyroid eye disease, setting stage for confirmatory phase 3
Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...
FierceBiotech3h
Umoja secures $100M series C to bring more CAR-Ts into the clinic
Umoja Biopharma has secured $100 million in series C funds as the cancer-focused biotech looks to bring more of its cell ...
FierceBiotech6h
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...
FierceBiotech9h
JPM25, Day 2: Trump admin health picks ‘like a box of chocolates’
Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...
FierceBiotech16h
JPM25: Medtronic begins rolling out adaptive brain stimulation for Parkinson's after EU approval
While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...
FierceBiotech17h
JPM25, Day 1: GSK's billion-dollar bet, Bayer's trial first, Lilly buys Scorpion, and more
It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...